<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3011">
  <stage>Registered</stage>
  <submitdate>20/07/2010</submitdate>
  <approvaldate>20/07/2010</approvaldate>
  <nctid>NCT01252420</nctid>
  <trial_identification>
    <studytitle>Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis</studytitle>
    <scientifictitle>Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER)</scientifictitle>
    <utrn />
    <trialacronym>TWISTER</trialacronym>
    <secondaryid>DDVTANZ</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous Thrombosis</healthcondition>
    <healthcondition>Pulmonary Embolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Enoxaparin

Treatment: drugs: Enoxaparin
1.5mg/kg daily for 2 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptomatic recurrence of venous thrombosis (DVT, non fatal and fatal pulmonary embolism) within 3 months.</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Asymptomatic proximal thrombus extension at 2 weeks</outcome>
      <timepoint>2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time course of symptom resolution and the proportion of patients with complete resolution at two weeks. - Time course of symptom resolution including time to complete resolution of symptoms, and the proportion of patients with complete resolution at two weeks.</outcome>
      <timepoint>2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Post-thrombotic syndrome</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Predictors of recurrent or progressive DVT or new PE</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients aged 18 years or older with acute symptomatic provoked or unprovoked distal
             vein thrombosis (axial or muscular veins but not involving trifurcation or distal
             popliteal vein)

          -  Absence of symptomatic pulmonary embolism</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  DVT involving trifurcation or more proximal leg veins on imaging

          -  Prior DVT

          -  Active malignancy ie present at time of diagnosis, or on treatment, or treatment
             completed within 3 months

          -  Ongoing risk factors for propagation e.g. immobility (&gt;50% of day in bed or =72
             hours), plaster cast or non-weight bearing

          -  Other indication for therapeutic anticoagulation (e.g. AF)

          -  Active gastro-oesophageal ulceration or bleeding

          -  Other high risk for bleeding (e.g. recent neurosurgery, vascular retinopathy,
             coagulopathy)

          -  Platelet count &lt;80 x 109/L

          -  Renal impairment (CrCl &lt;30ml/min)  Pregnancy or lactation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>330</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Prince of Wales Hospital - Sydney</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Monash Medical Centre, Southern Health - Melbourne</hospital>
    <postcode>2031 - Sydney</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3168 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Monash Medical Centre</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Southern Health, Victoria</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Eastern Health, Victoria</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Adelaide Hospital, Adelaide</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Prince of Wales Hospital, Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Christchurch Hospital, NZ</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Auckland City Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>North Shore Hospital, New Zealand</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Middlemore Hospital, New Zealand</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether a limited duration of treatment (two weeks
      of low molecular weight treatment) is a safe and effective treatment for distal deep vein
      thrombosis of the lower limb.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01252420</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Huyen Tran, MBBs(Hons), MClin Epidem</name>
      <address>Monash Medical Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>